Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2007

View Archived Issues

MEK inhibitor potentiates dasatinib-induced apoptosis of CML cells

New therapeutic agents for cancer imparted in recent patents

Phase II study of MKC-1 in advanced breast cancer cleared to continue

Transtec provides reliable analgesia in cancer pain patients

Recent Uriach and ProMetic patents impart novel treatments for immune and autoimmune disorders

Recent Hammersmith Imanet patent discloses novel diagnostic agents

NNZ-2566 is safe in phase I study

Actemra demonstrates significant improvement in signs and symptoms of RA

Preclinical characterization of SSR-180711, a novel selective alpha7 nAChRr partial agonist

GlaxoSmithKline reports on melanocortin 4 receptor agonists as novel antiobesity compounds

Novel nonpeptide GLP-1 receptor agonist exhibits antidiabetic efficacy in vivo

Intranasal insulin improves memory

BioProgress updates drug development progress

New trial evaluates oral cladribine with Rebif for MS

Renovis announces restructuring plan

Cell Therapeutics makes unsolicited offer for DOR BioPharma

LX-1031 begins phase I trials for IBS and GI disorders

Molecular Insight acquires radiotherapy candidate Onalta

ADX-10061 begins proof-of-concept study for smoking cessation

Avontec and Activaero sign development deal for inhaleable AVT01

New phase II trial studies OBE-101 for weight loss in obese patients

Barrow receives grant to support neurofibromatosis research

Kirin and Astellas collaborate on anti-CD40 antagonistic MAb

Suboxone available in U.K.

Toyama seeks clearance to begin U.S. studies of T-705

Irinotecan eluting beads safe and effective in GI cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...